Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2009-03-02
2011-10-18
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S236000
Reexamination Certificate
active
08039003
ABSTRACT:
The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
REFERENCES:
Men, R., et al., 1996, Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys, J. Virol. 70(6):3930-3937.
Bray, M., et al., 1996, Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge, J. Virol. 70(6):4162-4166.
R. Men et al., “Dengue Type 4 Virus Mutants Containing Deletions in the 3′ Noncoding Region of the RNA Genome: Analysis of Growth Restriction in Cell Culture and Altered Viremia Pattern and Immunogenicity in Rhesus Monkeys”, Journal of Virology, 70(6), pp. 3930-3937 (1996).
Blaney Joseph E.
Hanley Kathryn A.
Murphy Brian R.
Whitehead Stephen S.
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Parkin Jeffrey
The United States of America as represented by the Secretary, De
LandOfFree
Recombinant attenuated dengue viruses comprising a deletion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant attenuated dengue viruses comprising a deletion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant attenuated dengue viruses comprising a deletion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286772